Concept Foundation is happy to announce that Incepta Pharmaceuticals (Bangladesh) has been awarded WHO Prequalification of their intramuscular (IM) depot medroxyprogesterone acetate (DMPA) 150 mg/ml product. The Incepta product adds a second generic DMPA product to the WHO PQ list, alongside Mylan’s product, thereby increasing the volume of quality assured 3 monthly injectable contraception available worldwide

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial results have been released, finally providing long awaited answers to questions about the relationship between DMPA, the Implant and the Copper IUD and risk of HIV transmission in women.